ClinicalTrials.gg
CompletedNCT05702489Updated Nov 5, 2024

A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza

A Phase 2/3 interventional study of ZX-7101A in Influenza, Human, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-11-05.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2022, registered Jan 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
42nd of 157
900 · median 360
Started
2022
with 7 others
Phase 2/3
3 of 173
1 open now
Registered
117th of 173
by date
Lead sponsor
6 of 173
Nanjing Zenshine Pharmaceuticals

Among the 173 studies in Influenza, Human with a site in China, this one is the 42nd largest by enrollment of the 157 interventional ones that give a count, is one of 8 that started in 2022, is one of 3 in phase 2/3, and was the 117th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with uncomplicated influenza. The main questions it aims to answer are:

  • The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated influenza.
  • The safety of ZX-7101A in Chinese Adults patients with uncomplicated influenza.
03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 to ≤64 years of age at the time of signing the ICF.
  • Patients in the screening period met the following criteria: (1) rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive; (2) fever ≥ 37.3℃ (axillary temperature) at screening; if taking antipyretics, axillary temperature ≥ 37.3℃ after taking the drug (more than 4 hours). (3) At least one of flu-related systemic symptoms is moderate or greater in severity: a. muscle or joint pain, b. fatigue, c. headache, d. fever. (4) At least one of the influenza-related respiratory symptoms is moderate or greater in severity: a. nasal congestion, b. sore throat, c. cough.
  • The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization.

Exclusion criteria

Exclusion Criteria:

  • Patients with influenza virus infection requiring hospitalization.
  • High-risk population.
  • Bronchitis, pneumonia, pleural effusion or interstitial disease suspected by a clinician or confirmed by chest imaging [X-ray (anteroposterior or anteroposterior)/CT] and judged by the investigator at screening.
  • Patients who have developed acute respiratory tract infection, otitis media, and sinusitis within 2 weeks before screening.
  • Patients with other infections requiring systemic anti-infective treatment, or blood routine examination at screening: white blood cell count (WBC) > 10.0 × 109/L.
  • Patients with purulent sputum or suppurative tonsillitis.
  • Those who have difficulty in swallowing drugs or have a history of gastrointestinal diseases that seriously affect drug absorption.
  • Medications against influenza virus within 7 days prior to Screening.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
900 participants (actual)

Study arms

  • Experimental
    ZX-7101A low dose group

    40 mg, tablet, single oral administration when the subject screened successfully

    Drug: ZX-7101A

  • Experimental
    ZX-7101A high dose group

    80 mg, tablet, single oral adminitration when the subject screened successfully

    Drug: ZX-7101A

  • Placebo comparator
    Placebo control

    Analog tablet with no active ingredient, single oral administration when the subject screened successfully

    Drug: ZX-7101A

Interventions

  • a drug to treatment influenza in Chinese adults

06

What researchers measure

Primary outcomes

  1. The time to the remission of all influenza symptoms (hours)

    Defined as the time from the start of study treatment to the time all flu symptoms are relieved. Symptom relief was defined as all seven influenza symptoms assessed by the subject on the subject diary card(Stuffy nose, sore throat, cough, muscle or joint pain, fatigue, headache, fever or chills/sweating) were 0 (asymptomatic) or 1 (mild);

    Time frame: from accepting ZX-7101A until the 15 days after the first dosing

Secondary outcomes

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    The Number of Participants with Treatment-Related Adverse Event will be evalated as the change of vital signs, electrocardiogram (P Wave, QRS Complex, QT Interval), physical examination, and Laboratory test compared with the baseline.

    Time frame: from accepting ZX-7101A until the 15 days after the first dosing

07

Study locations

1 site
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2023, 10 months.

Of 10 phase 2/3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median); a quarter within 6 and three quarters within 12. This study's 10 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Jan 27, 2023
StartActual
Jul 17, 2022
Primary completionActual
May 26, 2023
CompletionActual
Oct 13, 2023
Last update
Nov 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05702489
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 27, 2023
Start date
Jul 17, 2022
Primary completion
May 26, 2023
Completion
Oct 13, 2023
Last update
Nov 5, 2024

Study contacts

hong wen Zhang, doctor
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebaloxavir marboxil

Start the discussion